Retatrutide

Retatrutide is a Triple Receptor Agonist supplied for laboratory research. Triple GIP, GLP-1, and glucagon receptor co-agonist studied in preclinical research for multi-receptor pharmacodynamics, energy expenditure pathway modeling, and lipid metabolism analysis.

Retatrutide is a triple receptor agonist acting on the GIP, GLP-1, and glucagon receptors, whereas semaglutide targets GLP-1 alone and tirzepatide targets GIP and GLP-1. This added glucagon-receptor activity is a key focus of current metabolic research.

Retatrutide is supplied as a lyophilized (freeze-dried) powder — a dehydrated form that keeps the peptide stable during shipping and storage. In the laboratory it is reconstituted (returned to liquid form) using a solvent such as bacteriostatic water, added slowly against the side of the vial, which is then swirled gently — never shaken — until the powder fully dissolves. All handling is for in vitro research use only.

Store the lyophilized Retatrutide powder at -20°C, protected from light and moisture, where it remains stable long-term. Once reconstituted, keep it refrigerated (2-8°C) and use it within the timeframe appropriate for your research protocol.

Every batch of Retatrutide is produced to a purity of 99% or higher. Purity and molecular identity are verified using standard analytical methods — high-performance liquid chromatography (HPLC) to measure purity, and mass spectrometry (MS) to confirm the peptide's molecular weight.